For the 30th edition of ECCMID, we would like to highlight 30 outstanding young scientists 30 years of age or younger.
https://www.eccmid.org/scientific_programme/30_under_30/
https://www.escmid.org/fileadmin/src/media/PDFs/FinalProgramme30under30_web-2.pdf
Dr. Prasanth Manohar is one of the extraordinary young scientists selected to represent the 30th edition of ECCMID 2020 (European Congress of Clinical Microbiology and Infectious Diseases).
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is one of the biggest clinical microbiology societies in the world comprising of Physicians, Medical Microbiologists, Health-care professionals, infectious disease scientists etc. Every year ESCMID conducts international conference to bring together world’s reputed scientists under one roof to discuss up-to-date research outcome in the field of clinical microbiology and infectious diseases. This year for its 30th edition of ECCMID 2020 in Paris, France, the European society decides to select 30 extraordinary young scientists (under the age of 30) around the globe. The applications were invited from young scientists around the world for this“30 under 30”program. Accordingly, 30 young scientists were selected globally including Dr. Prasanth. Born in a small village in Karur district, Dr. Prasanth had completed his Ph.D. in Vellore Institute of Technology (VIT) and pursuing his post-doctoral studies in Zhejiang University, China. Notably, earlier in 2016 he won the young scientist award from European Union, INNO Indigo projects, for his research in phage therapy.
When talking about his research Dr. Prasanth explained, “Antibiotic resistance is one of the emerging global health problems which need immediate attention. Phage therapy is the use of live bacteriophages to treat infectious diseases caused by bacteria. Due to uncontrolled and irrational use of antibiotics, bacteria are developing resistance against almost all the available antibiotics in the market. Therefore, it is impossible to use antibiotics to treat any bacterial infections such as pneumonia to surgical wounds. So it is important to find alternative therapy to treat antibiotic resistant bacterial infections. Bacteriophages or bacteria eaters can be used to infect or kill bacteria which is popularly known as “phage therapy”. Research on bacteriophage therapy is growing faster than ever to meet the global need for alternative therapy. With my 6+ years of continuous research on bacteriophage biology it has now lead me to pursue clinical trials. In future, my research will focus on clinical trials and clinical outcome of phage therapy. Brining therapeutic use of bacteriophages to treat patients will be one of my greatest successes in research as a phage scientist.
PHAGElogist 